Tamiflu

An acetamido cyclohexene that is a structural homolog of sialic acid and inhibits neuraminidase. .
[PubChem].

Medicinal name:
  • Oseltamivir 75 MG Oral Capsule [Tamiflu]
  • Oseltamivir 45 MG Oral Capsule [Tamiflu]
  • Oseltamivir 30 MG Oral Capsule [Tamiflu]

Tamiflu - Pharmacology:

Tamiflu is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

Tamiflu mini report

Tamiflu NDA
NDA - A product marketed under an approved New Drug Application
Tamiflu CAPSULE
CAPSULE
Tamiflu POWDER, FOR SUSPENSION
POWDER, FOR SUSPENSION
Tamiflu HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Tamiflu global name
oseltamivir phosphate
Tamiflu global name
Oseltamivir Phosphate
Start - Stop data
START DATA:
1999-Oct-27
Start - Stop data
STOP DATA
not occurred

Tamiflu for patients

Patients should be instructed to begin treatment with TAMIFLU as soon as possible from the first appearance of flu symptoms. Similarly, prevention should begin as soon as possible after exposure, at the recommendation of a physician.

Patients should be instructed to take any missed doses as soon as they remember, except if it is near the next scheduled dose (within 2 hours), and then continue to take TAMIFLU at the usual times.

TAMIFLU is not a substitute for a flu vaccination. Patients should continue receiving an annual flu vaccination according to guidelines on immunization practices.

Tamiflu Interactions

Information derived from pharmacology and pharmacokinetic studies of oseltamivir suggests that clinically significant drug interactions are unlikely.

Tamiflu is extensively converted to oseltamivir carboxylate by esterases, located predominantly in the liver. Drug interactions involving competition for esterases have not been extensively reported in literature. Low protein binding of oseltamivir and oseltamivir carboxylate suggests that the probability of drug displacement interactions is low.

In vitro studies demonstrate that neither oseltamivir nor oseltamivir carboxylate is a good substrate for P450 mixed-function oxidases or for glucuronyl transferases.

Cimetidine, a non-specific inhibitor of cytochrome P450 isoforms and competitor for renal tubular secretion of basic or cationic drugs, has no effect on plasma levels of oseltamivir or oseltamivir carboxylate.

Clinically important drug interactions involving competition for renal tubular secretion are unlikely due to the known safety margin for most of these drugs, the elimination characteristics of oseltamivir carboxylate (glomerular filtration and anionic tubular secretion) and the excretion capacity of these pathways. Coadministration of probenecid results in an approximate twofold increase in exposure to oseltamivir carboxylate due to a decrease in active anionic tubular secretion in the kidney. However, due to the safety margin of oseltamivir carboxylate, no dose adjustments are required when coadministering with probenecid.

Coadministration with amoxicillin does not alter plasma levels of either compound, indicating that competition for the anionic secretion pathway is weak.

In six subjects, multiple doses of oseltamivir did not affect the single-dose pharmacokinetics of acetaminophen.

Tamiflu Contraindications

TAMIFLU is contraindicated in patients with known hypersensitivity to any of the components of the product.

Manufacturers name:

  • REMEDYREPACK INC
  • Physicians Total Care, Inc
  • Genentech, Inc
  • Dispensing Solutions, Inc
  • Rebel Distributors Corp

Tamiflu tags categories:

Generic name, Overdose, Half Life Tamiflu, Food Interactions, Chemical, etc..

Tamiflu see also FDA report

Antibiotics

Chemical structure:
O O O N O N H H H H H H H H H H H H H H H H H H H H H H H H H H H H C16H28N2O4 2D chemical structure C16H28N2O4 SVG | 2D structure chemical names, chemical properties, classification C16H28N2O4